News

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...
PharmTech31m
Sustainable Alternative: PFAS-Free-TPE for Pharmaceutical Stoppers
Thermoplastic elastomers (TPE) offer a PFAS-free solution for stoppers in parenteral packaging, ensuring a safer and more ...
89bio: Promising As Pegozafermin Nears Phase 3 Readout
Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & ...
Trump tariffs live updates: Nvidia and AMD agree to unusual revenue deal, China deadline looms
Nvidia and AMD have reportedly agreed to pay the US 15% of the revenue for AI-related chip sales to China, adding a ...